Rabbit Recombinant Monoclonal ZNFX1 antibody. Suitable for WB and reacts with Human samples. Cited in 4 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
IP | Flow Cyt | WB | IHC-P | ICC/IF | |
---|---|---|---|---|---|
Human | Not recommended | Not recommended | Tested | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 - 1/5000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
RNA-binding protein that initiates the antiviral response and is required to restrict the replication of RNA viruses (PubMed:33872655). Acts as a double-stranded RNA (dsRNA) sensor that recognizes viral RNA and then interacts with MAVS to initiate the type I interferon response (By similarity). Also required for immunity against some bacteria, such as mycobacteria (PubMed:33876776).
KIAA1404, ZNFX1, NFX1-type zinc finger-containing protein 1
Rabbit Recombinant Monoclonal ZNFX1 antibody. Suitable for WB and reacts with Human samples. Cited in 4 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
The zinc finger NFX1-type containing 1 (ZNFX1) protein is a DNA-binding protein involved in nucleic acid sensing and immune regulation. It is also known as ZNF-X1. ZNFX1 has a mass of approximately 119 kDa. It expresses in various tissues with notably higher expression levels in the spleen lymph nodes and blood cells. The protein features zinc finger domains which facilitate its interaction with nucleic acids enabling ZNFX1 to play a role in transcriptional regulation and the antiviral response.
ZNFX1 influences immune function and viral defense mechanisms. Acting within ribonucleoprotein complexes it participates in the sensing of double-stranded RNA an indicator of viral infection. ZNFX1 helps modulate type I interferon responses a critical aspect of host defense. In these processes it interacts with other proteins necessary for the immune system contributing to maintaining cellular immune surveillance and controlling viral replication.
The actions of ZNFX1 integrate into pathways related to RNA processing and immune responses. Specifically ZNFX1 is involved in the RIG-I-like receptor (RLR) pathway which is important for antiviral responses. In this pathway ZNFX1 interacts with proteins like RIG-I and MAVS to facilitate the proper functioning of antiviral signaling cascades. This pathway's coordination leads to the activation of transcription factors that promote the expression of type I interferons and other cytokines essential for antiviral immunity.
ZNFX1 associates with immunological conditions including systemic lupus erythematosus (SLE). Abnormalities in ZNFX1 function or expression may contribute to the dysregulation of immune response observed in this autoimmune disease. Furthermore ZNFX1 connects with proteins such as TREX1 known to be involved in the pathogenesis of SLE through the management of immune signaling and prevention of excessive immune activation. Understanding these relationships highlights the significance of ZNFX1 in both normal and disease states of the immune system.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-ZNFX1 antibody [EPR12330] (ab179452) at 1/1000 dilution
All lanes: K-562 (Human chronic myelogenous leukemia lymphoblast) whole cell lysate at 15 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 220 kDa
Observed band size: 220 kDa
All lanes: Western blot - Anti-ZNFX1 antibody [EPR12330] (ab179452) at 1/1000 dilution
Lane 1: MCF7 cell lysate at 10 µg
Lane 2: K562 cell lysate at 10 µg
Lane 3: HeLa cell lysate at 10 µg
Predicted band size: 220 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com